Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Caper CRISPR/Cas9 KO Plasmid (h): sc-416921
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Caper CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Caper genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Caper Antibody (G-10): sc-376531
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Caper CRISPR/Cas9 KO Plasmid (h) | sc-416921 | 20 µg | $397.00 |
Overview
RBM39 encodes the human RNA-binding protein Caper, a nuclear splicing factor that couples transcription to pre-mRNA processing through interactions with spliceosomal components and transcriptional co-regulators. Caper contributes to alternative splicing decisions and RNA metabolism programs that shape cell-cycle progression, differentiation, and stress-responsive gene expression. Dysregulated RBM39 activity and aberrant splicing patterns have been linked to oncogenic signaling outputs and altered proteome composition in multiple tumor contexts. As a result, RBM39 is frequently studied to connect spliceosome function with pathway rewiring and RNA-driven mechanisms of disease-relevant phenotypes.
Caper CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RBM39 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RBM39 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RBM39 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Caper protein expression.
This CRISPR knockout system enables efficient generation of RBM39-deficient cell models for investigation of Caper signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RBM39 exon(s) critical for Caper function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RBM39 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Caper CRISPR/Cas9 KO Plasmid (h) and Caper CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RBM39 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Caper HDR Plasmid (h) and Caper HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RBM39 homology arms to support homology-directed repair at defined RBM39 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.